Andrea Schneider, Ph.D. for UC Davis Health

Andrea Schneider, Ph.D.

Associate Research Scientist




Clinical Psychology



Locations and Contact

2825 50th St.
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone


Clinic Phone


Clinic Fax


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

I am a researcher-clinician and deliver state-of-the-art patient- and family-centered care for neurodevelopmental and neurodegenerative disorders. 

My work mostly focuses on Fragile X-related disorders, premutation carrier issues, and support for autism spectrum disorders and ADHD. 

Here at the MIND Institute we are proud to be working together as a team, respecting and embracing each person's individuality and socio-cultural community.

Clinical Interests

Dr. Schneider is strongly committed to understanding, prevention, care, and cure of neurodevelopmental and neurodegenerative disorders.

Dr. Schneider has extensive experience in the administration of neuropsychological and psychiatric assessments, especially for executive function, social cognition, and intellectual impairments.

Research/Academic Interests

Dr. Andrea Schneider has over 20 years of experience working in the field of neurodevelopmental and neurodegenerative disorders. As a researcher and licensed psychologist, she integrates translational research with her clinical background that provides unique insights individuals affected by fragile X-related disorders. Dr. Schneider's main research interest is the association between genetic and brain abnormalities underlying the neuropsychopathology, behavioral, and psychiatric symptoms in individuals with the fragile X mutations. Her focus on a number of psychophysiological indicators, like EEG/ERP measures in fragile X spectrum disorders and ASD, prepulse inhibition, eye tracking, and biofeedback.


Child Development and Behavior

Center/Program Affiliation

UC Davis MIND Institute

Medical School

Ph.D., University of Postdam, Potsdam, Germany 2007

Other School

MSc. (not finished), Humboldt University, Charite, Berlin, Germany


Psychology, Ambulatory Care Center, University of Potsdam, Potsdam, Germany 2001-2003


DBP/Fragile X Syndrome, UC Davis MIND Institute, Sacramento CA 2008-2011

To view a full list of publications for Dr. Andrea Schneider, please click here.

Schneider A, Winarni TI, Cabal-Herrera AM, Bacalman S, Gane L, Hagerman P, Tassone F, Hagerman R. Elevated FMR1-mRNA and lowered FMRP - A double-hit mechanism for psychiatric features in men with FMR1 premutations. Transl Psychiatry. 2020 Jun 23;10(1):205. doi:10.1038/s41398-020-00863-w. PMID:32576818. PMCID:PMC7311546.

Aydin EY, Schneider A, Protic D, Wang JY, Martínez-Cerdeño V, Tassone F, Tang HT, Perlman S, Hagerman RJ. Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease. Clin Interv Aging. 2020;15:285-292. doi:10.2147/CIA.S240314. eCollection 2020. PMID:32161452. PMCID:PMC7051898.

Santos E, Emeka-Nwonovo C, Wang JY, Schneider A, Tassone F, Hagerman P, Hagerman R. Developmental aspects of FXAND in a man with the FMR1 premutation. Mol Genet Genomic Med. 2020 Feb;8(2):e1050. doi:10.1002/mgg3.1050. Epub 2020 Jan 3. PMID:31899609. PMCID:PMC7005639.

Kim K, Hessl D, Randol JL, Espinal GM, Schneider A, Protic D, Aydin EY, Hagerman RJ, Hagerman PJ. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS One. 2019;14(12):e0226811. doi:10.1371/journal.pone.0226811. eCollection 2019. PMID:31891607. PMCID:PMC6938341.

Potter LA, Scholze DA, Biag HMB, Schneider A, Chen Y, Nguyen DV, Rajaratnam A, Rivera SM, Dwyer PS, Tassone F, Al Olaby RR, Choudhary NS, Salcedo-Arellano MJ, Hagerman RJ. A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Front Psychiatry. 2019;10:810. doi:10.3389/fpsyt.2019.00810. eCollection 2019. PMID:31780970. PMCID:PMC6851992.

Biag HMB, Potter LA, Wilkins V, Afzal S, Rosvall A, Salcedo-Arellano MJ, Rajaratnam A, Manzano-Nunez R, Schneider A, Tassone F, Rivera SM, Hagerman RJ. Metformin treatment in young children with fragile X syndrome. Mol Genet Genomic Med. 2019 Nov;7(11):e956. doi:10.1002/mgg3.956. Epub 2019 Sep 14. PMID:31520524. PMCID:PMC6825840.

Protic D, Aydin EY, Tassone F, Tan MM, Hagerman RJ, Schneider A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. Mol Genet Genomic Med. 2019 Jul;7(7):e00745. doi:10.1002/mgg3.745. Epub 2019 May 18. PubMed PMID:31104364. PMCID:PMC6625129.

Napoli E, Schneider A, Wang JY, Trivedi A, Carrillo NR, Tassone F, Rogawski M, Hagerman RJ, Giulivi C. Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. Mol Neurobiol. 2019 May;56(5):3702-3713. doi:10.1007/s12035-018-1330-3. Epub 2018 Sep 5. PMID:30187385. PMCID:PMC6401336.

Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-Associated Neuropsychiatric Disorders (FXAND). Front Psychiatry. 2018;9:564. doi:10.3389/fpsyt.2018.00564. eCollection 2018. PMID:30483160. PMCID:PMC6243096.

El-Deeb M, Adams P, Schneider A, Salcedo-Arellano MJ, Tassone F, Hagerman R. Fentanyl overdose in a female with the FMR1 premutation and FXTAS. J Mol Genet (Isleworth). 2018 Nov;1(1). doi:10.31038/JMG.1000101. Epub 2018 Apr 1. PMID:31032490. PMCID:PMC6482838.